Options
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
Journal
JTO clinical and research reports
Journal Volume
5
Journal Issue
2
Date Issued
2024-02
Author(s)
Nishino, Kazumi
Nakagawa, Kazuhiko
Reck, Martin
Garon, Edward B
Carlsen, Michelle
Matsui, Tomoko
Visseren-Grul, Carla
Nadal, Ernest
Abstract
EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating mutation. This exploratory analysis evaluated potential associations between EGFR exon 19 deletion (ex19del) variants and clinical outcomes.
Subjects
Carcinoma; EGFR exon 19 deletion variant; Non–small cell lung; Ramucirumab; Targeted therapy; VEGFR inhibition
Type
journal article